Search clinical trials for: Tislelizumab

Total 434 results

The First Affiliated Hospital of Xiamen University

Recruiting

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) (SEGNO)

Oligometastatic Prostate Cancer | Locally Advanced Prostate Cancer

China
XIANG YANQUN

Recruiting

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Nasopharyngeal Carcinoma

China
Ji Yongling

Not yet recruiting

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Non-Small Cell Lung Cancer
Xiangdong Cheng
Shanxi Province Cancer Hospital; The Second Affiliated Hospital of Harbin Medical... and other collaborators

Not yet recruiting

Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.

Gastric Cancer

China
Beijing Chest Hospital, Capital Medical University

Not yet recruiting

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC (NeoSCLC-001)

Limited-stage Small-cell Lung Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer Neck
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Bladder Cancer

China
Zhongnan Hospital

Not yet recruiting

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Endometrial Neoplasms

China
The First Affiliated Hospital, Guangzhou University...

Not yet recruiting

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Advanced NSCLC
Jing-yuan Fang, MD, Ph. D

Recruiting

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Colorectal Cancer

China
The Affiliated Hospital of Qingdao University

Recruiting

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer (PILOT)

Non-small-cell Lung Cancer (NSCLC)

China
Jiangsu Healthy Life Innovation Medical Technology...

Not yet recruiting

TTField in Combination With TMZ and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

Glioblastoma Multiforme
Daping Hospital and the Research Institute of Surgery...

Recruiting

PPIO-008S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY

Postoperative Assistance for Esophageal Squamous Cell Carcinoma With Negative Lymph Nodes

China
Sichuan University

Not yet recruiting

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Solid Tumor
Sun Yat-sen University

Recruiting

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Lenvatinib | Hepatic Arterial Infusion Chemotherapy

China
Fujian Cancer Hospital

Not yet recruiting

A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer

Mid-low Rectal Cancer
Gustave Roussy, Cancer Campus, Grand Paris
BeiGene; C2i Genomics

Not yet recruiting

tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (UMBRELLA)

Soft Tissue Sarcoma | Cancer | Lung Cancer | Pancreas Cancer | Colo-rectal Cancer

France
Fujian Cancer Hospital

Not yet recruiting

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Metastatic Nasopharyngeal Carcinoma | Intermittent Systematic Chemotherapy
Sun Yat-sen University

Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Bevacizumab | Anti-PD1/PDL1 Antibody

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Beijing Friendship Hospital
Changhai Hospital; The First Affiliated Hospital of Anhui Medical University; Fudan University and other collaborators

Recruiting

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study

Locally Advanced Rectal Carcinoma

China
West China Hospital

Not yet recruiting

SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Gastric Cancer
Sun Yat-sen University

Recruiting

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Immunotherapy | DMMR Colorectal Cancer | Anti PD-1

China
Lai-ping Zhong
Sun Yat-sen University; Fudan University; Fujian Medical University; Central South...

Recruiting

Neoadjuvant Immunochemotherapy for LAOSCC

Oral Squamous Cell Carcinoma | Locally Advanced Head and Neck Carcinoma

China
First Affiliated Hospital of Guangxi Medical University

Recruiting

The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

Rectal Cancer | Rectal Cancer Stage II | Rectal Cancer Stage III

China
First Affiliated Hospital Bengbu Medical College

Not yet recruiting

Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Pengyuan Liu

Recruiting

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (CRPC)

China
First Affiliated Hospital of Wenzhou Medical University

Not yet recruiting

Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

Gastric Cancer
Qilu Hospital of Shandong University
BeiGene

Recruiting

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Xiang Lu

Recruiting

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell Carcinoma

China
BeiGene

Not yet recruiting

Study of BG-C9074 as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

Hepatocellular Carcinoma | Radiotherapy | Tislelizumab | Tumor Thrombosis

China
Fujian Cancer Hospital

Not yet recruiting

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Colo-rectal Cancer
Fudan University

Recruiting

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma | Renal Clear Cell Carcinoma

China
Li Xiao Wei

Not yet recruiting

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) (HAI-TL)

Hepatocellular Carcinoma With PVTT

China
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Peking University

Recruiting

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Liver Metastasis Colon Cancer | MSS | ctDNA Genotype | Failed From Standard Treatment

China
Fujian Cancer Hospital

Not yet recruiting

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Gastric Cancer
Fudan University

Recruiting

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Nasopharyngeal Carcinoma

China
University Health Network, Toronto

Not yet recruiting

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (ZanTisle)

Large B-cell Lymphoma
Nanfang Hospital, Southern Medical University

Recruiting

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Gastric Cancer

China
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
Sun Yat-sen University

Recruiting

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Recruiting

Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer

Untreated Advanced Non-small Cell Lung Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Carcinoma | Intrahepatic Cholangiocarcinoma | Gallbladder Cancer | Immunotherapy | Tislelizumab | Surufatinib | Angiogenesis Inhibitors | Antineoplastic Agents, Immunological
West China Hospital

Not yet recruiting

Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC

NSCLC Associated With Leptomeningeal Metastases
Xuekui Liu

Not yet recruiting

A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. (B2023-153)

Oral Squamous Cell Carcinoma
First Affiliated Hospital of Guangxi Medical University

Recruiting

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

Colonic Neoplasms | Neoadjuvant Therapy | Immune Checkpoint Inhibitors

China
China Medical University, China

Not yet recruiting

Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

Colorectal Adenocarcinoma | Gastric

China

3

Subscribe